Neurodegenerative diseases: Quantitative predictions of protein-RNA interactions

RNA

Volumn 19, Issue 2, 2013, Pages 129-140

  Cirillo, Davide ^a,b   Agostini, Federico ^a,b   Klus, Petr ^a,b   Marchese, Domenica ^a,b   Rodriguez, Silvia ^a,b   Bolognesi, Benedetta ^a,b   Tartaglia, Gian Gaetano ^a,b  

^a CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Autogenous regulation; Neurodegeneration; Noncoding RNA; Protein RNA interactions; RNA aptamers

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; FRAGILE X MENTAL RETARDATION PROTEIN; TAR DNA BINDING PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; INTELLECTUAL IMPAIRMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING;

ALGORITHMS; ALPHA-SYNUCLEIN; AMYLOID BETA-PROTEIN PRECURSOR; APTAMERS, NUCLEOTIDE; DNA-BINDING PROTEINS; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENE EXPRESSION REGULATION; HUMANS; MALE; MODELS, THEORETICAL; NEURODEGENERATIVE DISEASES; PRIONS; PROTEIN BINDING; RIBONUCLEOPROTEINS; RNA; RNA, UNTRANSLATED; RNA-BINDING PROTEINS;

EID: 84872525680     PISSN: 13558382     EISSN: 14699001     Source Type: Journal    
DOI: 10.1261/rna.034777.112     Document Type: Article

References (55)

1. Agostini F, Cirillo D, Bolognesi B, Tartaglia GG. 2012. X-inactivation: Quantitative predictions of protein interactions in the Xist network. Nucleic Acids Res doi: 10.1093/nar/gks968.
2. Anthony K, Gallo J-M. 2010. Aberrant RNA processing events in neurological disorders. Brain Res 1338: 67-77.
3. Ayala YM, De Conti L, Avendaño-Vázquez SE, Dhir A, Romano M, D'Ambrogio A, Tollervey J, Ule J, Baralle M, Buratti E, et al. 2011. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J 30: 277-288.
4. Bartzokis G, Sultzer D,CummingsJ, Holt LE, HanceDB, HendersonVW, Mintz J. 2000. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry 57: 47-53.
5. Bechara EG, Didiot MC, Melko M, Davidovic L, Bensaid M, Martin P, Castets M, Pognonec P, Khandjian EW, Moine H, et al. 2009. A novel function for fragile X mental retardation protein in translational activation. PLoS Biol 7: e16.
6. Bellucci M, Agostini F, Masin M, Tartaglia GG. 2011. Predicting protein associations with long noncoding RNAs. Nat Methods 8: 444-445.
7. Buttarelli FR, Circella A, Pellicano C, Pontieri FE. 2006. Dopamine transporter immunoreactivity in peripheral blood mononuclear cells in amyotrophic lateral sclerosis. Eur J Neurol 13: 416-418.
8. Chen-Plotkin AS, Lee VM-Y, Trojanowski JQ. 2010. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol 6: 211-220.
9. Cho H-H, Cahill CM, Vanderburg CR, Scherzer CR, Wang B, Huang X, Rogers JT. 2010. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J Biol Chem 285: 31217-31232.
10. Darnell JC, Jensen KB, Jin P, Brown V, Warren ST, Darnell RB. 2001. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell 107: 489-499.
11. Darnell JC, Fraser CE, Mostovetsky O, Stefani G, Jones TA, Eddy SR, Darnell RB. 2005. Kissing complex RNAs mediate interaction between the Fragile-X mental retardation protein KH2 domain and brain polyribosomes. Genes Dev 19: 903-918.
12. Davidovic L, Navratil V, Bonaccorso CM, Catania MV, Bardoni B, Dumas M-E. 2011. A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model. Genome Res 21: 2190-2202.
13. Deleault NR, Lucassen RW, Supattapone S. 2003. RNA molecules stimulate prion protein conversion. Nature 425: 717-720.
14. Dobson CM. 1999. Protein misfolding, evolution and disease. Trends Biochem Sci 24: 329-332.
15. Fiesel FC, Kahle PJ. 2011. TDP-43 and FUS/TLS: Cellular functions and implications for neurodegeneration. FEBS J 278: 3550-3568.
16. Fiesel FC, Schurr C, Weber SS, Kahle PJ. 2011. TDP-43 knockdown impairs neurite outgrowth dependent on its target histone deacetylase 6. Mol Neurodegener 6: 64.
17. Geser F, Martinez-Lage M, Kwong LK, Lee VM-Y, Trojanowski JQ. 2009. Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: The TDP-43 diseases. J Neurol 256: 1205-1214.
18. Hagerman PJ, Hagerman RJ. 2004. The fragile-X premutation: A maturing perspective. Am J Hum Genet 74: 805-816.
19. Itoh M, Haga I, Li Q-H, Fujisawa J. 2002. Identification of cellular mRNA targets for RNA-binding protein Sam68. Nucleic Acids Res 30: 5452-5464.
20. Iwashita K, Ikeda R, Takeda Y, Sumizawa T, Furukawa T, Yamaguchi T, Akiyama S, Yamada K. 2010. Major vault protein forms complexes with hypoxia-inducible factor (HIF)-1α and reduces HIF-1α level in ACHN human renal adenocarcinoma cells. Cancer Sci 101: 920-926.
21. Jin P, Duan R, Qurashi A, Qin Y, Tian D, Rosser TC, Liu H, Feng Y, Warren ST. 2007. Pur α binds to rCGG repeats and modulates repeat- mediated neurodegeneration in a Drosophila model of Fragile X Tremor/Ataxia Syndrome. Neuron 55: 556-564.
22. Johnsen M, Christensen T, Dennis PP, Fiil NP. 1982. Autogenous control: Ribosomal protein L10-L12 complex binds to the leader sequence of its mRNA. EMBO J 1: 999-1004.
23. Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. 2009. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 284: 20329-20339.
24. Kedersha NL, Rome LH. 1986. Isolation and characterization of a novel ribonucleoprotein particle: Large structures contain a single species of small RNA. J Cell Biol 103: 699-709.
25. Kenneson A, Zhang F, Hagedorn CH, Warren ST. 2001. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet 10: 1449-1454.
26. Kim HD, Kim T-S, Joo YJ, Shin H-S, Kim S-H, Jang C-Y, Lee CE, Kim J. 2010. RpS3 translation is repressed by interaction with its own mRNA. J Cell Biochem 110: 294-303.
27. Kryshtafovych A, Venclovas C, Fidelis K, Moult J. 2005. Progress over the first decade of CASP experiments. Proteins 61 (Suppl 7): 225-236.
28. Lagier-Tourenne C, Cleveland DW. 2009. Rethinking ALS: The FUS about TDP-43. Cell 136: 1001-1004.
29. Lee JF, Stovall GM, Ellington AD. 2006. Aptamer therapeutics advance. Curr Opin Chem Biol 10: 282-289.
30. Lee EB, Lee VM-Y, Trojanowski JQ. 2012. Gains or losses: Molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci 13: 38-50.
31. Mercey R, Lantier I, Maurel M-C, Grosclaude J, Lantier F, Marc D. 2006. Fast, reversible interaction of prion protein with RNA aptamers containing specific sequence patterns. Arch Virol 151: 2197-2214.
32. Olivares D, Huang X, Branden L, Greig NH, Rogers JT. 2009. Physiological and pathological role of α-synuclein in Parkinson's disease through iron mediated oxidative stress; The role of a putative iron-responsive element. Int J Mol Sci 10: 1226-1260.
33. Oostra BA, Willemsen R. 2009. FMR1: A gene with three faces. Biochim Biophys Acta 1790: 467-477.
34. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE. 1993. Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci 90: 10962-10966.
35. Philpott CC, Klausner RD, Rouault TA. 1994. The bifunctional iron-responsive element binding protein/cytosolic aconitase: The role of active- site residues in ligand binding and regulation. Proc Natl Acad Sci 91: 7321-7325.
36. Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, Nelson DL. 1991. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66: 817-822.
37. Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling S-C, Sun E, Wancewicz E, Mazur C, et al. 2011. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14: 459-468.
38. Primerano B, Tassone F, Hagerman RJ, Hagerman P, Amaldi F, Bagni C. 2002. Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA 8: 1482-1488.
39. Proske D, Gilch S,Wopfner F, Schätzl HM, Winnacker E-L, Famulok M. 2002. Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem 3: 717-725.
40. Prusiner SB. 1998. Prions. Proc Natl Acad Sci 95: 13363-13383.
41. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, et al. 2002. An iron-responsive element type II in the 5'-untranslated region of the alzheimer's amyloid precursor protein transcript. J Biol Chem 277: 45518-45528.
42. Rubinsztein DC. 2006. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443: 780-786.
43. Salta E, De Strooper B. 2012. Non-coding RNAs with essential roles in neurodegenerative disorders. Lancet Neurol 11: 189-200.
44. Schaeffer C, Bardoni B, Mandel J-L, Ehresmann B, Ehresmann C, Moine H. 2001. The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif. EMBO J 20: 4803-4813.
45. Sellier C, Rau F, Liu Y, Tassone F, Hukema RK, Gattoni R, Schneider A, Richard S, Willemsen R, Elliott DJ, et al. 2010. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J 29: 1248-1261.
46. Silva JL, Vieira TCRG, Gomes MPB, Rangel LP, Scapin SMN, Cordeiro Y. 2011. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion. Methods 53: 306-317.
47. Strong MJ, Volkening K, Hammond R, Yang W, Strong W, Leystra- Lantz C, Shoesmith C. 2007. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci 35: 320-327.
48. Subramanian M, Rage F, Tabet R, Flatter E, Mandel J-L, Moine H. 2011. G-quadruplex RNA structure as a signal for neurite mRNA targeting. EMBO Rep 12: 697-704.
49. Tartaglia GG, Cavalli A, Pellarin R, Caflisch A. 2005. Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences. Protein Sci 14: 2723-2734.
50. Tartaglia GG, Pawar AP, Campioni S, Dobson CM, Chiti F, Vendruscolo M. 2008. Prediction of aggregation-prone regions in structured proteins. J Mol Biol 380: 425-436.
51. Tassone F, Hagerman RJ, Loesch DZ, Lachiewicz A, Taylor AK, Hagerman PJ. 2000. Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA. Am J Med Genet 94: 232-236.
52. Tremblay C, St-Amour I, Schneider J, Bennett DA, Calon F. 2011. Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol 70: 788-798.
53. Walden WE, Selezneva AI, Dupuy J, Volbeda A, Fontecilla-Camps JC, Theil EC, Volz K. 2006. Structure of dual function iron regulatory protein 1 complexed with ferritin IRE-RNA. Science 314: 1903-1908.
54. Westmark CJ, Malter JS. 2007. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol 5: e52.
55. Wilson AC, Dugger BN, Dickson DW, Wang D-S. 2011. TDP-43 in aging and Alzheimer's disease - a review. Int J Clin Exp Pathol 4: 147-155.